Michael Castagna - 23 Mar 2026 Form 4 Insider Report for MANNKIND CORP (MNKD)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: MNKD
Reported as of: 23 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 25 Mar 2026, 21:30:07 UTC
Prior SEC filing: 08 May 2026
Next SEC filing: 13 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Michael Castagna

Key filing fact

Michael Castagna filed Form 4 for MANNKIND CORP (MNKD) on 25 Mar 2026.

Key facts

This page summarizes Michael Castagna's Form 4 filing for MANNKIND CORP (MNKD).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 25 Mar 2026, 21:30.

Change

Previous filing in this sequence was filed on 08 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001674282 Primary reporting owner

Castagna Michael

Relationship: Chief Executive Officer, Director
Address: 1 CASPER STREET, DANBURY
Signature: /s/ Michael Castagna
Signature date: 25 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MNKD transaction Derivative

Performance Restricted Stock Unit

Award

Transaction value
Shares: +796,000
Change %
Price: $0.000000^*
Shares after: 796,000
Date: 23 Mar 2026
Ownership: Direct
Underlying class: Common Stock, $0.01 Par Value
Underlying amount: 796,000
Exercise price
Footnotes: F1, F2

MNKD transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value
Shares: +782,000
Change %
Price: $0.000000^*
Shares after: 782,000
Date: 23 Mar 2026
Ownership: Direct
Underlying class: Common Stock, $0.01 Par Value
Underlying amount: 782,000
Exercise price: $2.44
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.

Footnote F2

The performance-based restricted stock unit will vest on January 15, 2029. The number of shares delivered on the vesting date, as a percentage of the target specified [in Box 5 above], is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from April 1, 2026 until December 31, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the measurement period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.

Footnote F3

25% vesting on March 23, 2027 and thereafter 1/16th quarterly.